Palisade Bio (PALI) Corporate presentation summary

Corporate highlights and strategy

• Lead asset PALI-2108 is a once-daily, oral PDE4 inhibitor prodrug targeting ulcerative colitis (UC) and fibrostenotic Crohn's disease (FSCD), addressing a multi-billion-dollar IBD market.

• Raised $138 million from institutional healthcare investors, with $133 million cash as of October 2025, supporting major development milestones.

• PALI-2108 is the only PDE4 inhibitor prodrug in development for terminal ileum and colon, with dual anti-inflammatory and anti-fibrotic action for FSCD.

• Precision medicine CDx test in development to identify UC patient responders, aiming to improve treatment outcomes.

Clinical development and milestones

• Phase 1a/b studies completed for UC and FSCD, demonstrating safety, tolerability, and pharmacokinetics supporting local bioactivation.

• Phase 1b FSCD cohort ongoing, with topline data expected Q1 2026; Phase 2 for UC and FSCD planned to start in 2026.

• Upcoming milestones include IND clearance, Phase 2 dosing, and primary efficacy readouts for both indications through 2028.

Differentiation and mechanism of action

• PALI-2108 is a potent, selective PDE4 inhibitor prodrug with 10–20x potency over other PDE4 inhibitors, targeting the ileum and colon for improved efficacy and tolerability.

• Localized GI bioactivation minimizes systemic exposure and adverse events, with activation by colonic bacterial enzymes.

• Dual mechanism delivers anti-inflammatory and anti-fibrotic effects, with additional pro-kinetic benefits for FSCD.